{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"52","upperLimit":"85.8","value":"71"},{"groupId":"OG001","lowerLimit":"64.7","upperLimit":"84","value":"75.3"},{"groupId":"OG002","lowerLimit":"29.9","upperLimit":"80.2","value":"56.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"85"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"description":"Response criteria are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. response requires 50% reduction in lymph node size.","dispersionType":"95% Confidence Interval","groups":[{"description":"PCI-32765: 420 mg daily or 840 mg daily","id":"OG000","title":"Treatment Naive"},{"description":"PCI-32765: 420 mg daily or 840 mg daily","id":"OG001","title":"Relapsed/ Refractory"},{"description":"Food-Effect Relapsed/refractory participants received PCI-32765 420 mg daily","id":"OG002","title":"Food Effect"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).","title":"Percentage of Participants Achieving Response","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}